Clinical Trials Logo

Filter by:
NCT ID: NCT00065572 Suspended - Clinical trials for Carcinoma, Renal Cell

Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV)

Start date: August 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the biological activity of ZD6126 in subjects with newly diagnosed metastatic renal cell carcinoma (stage IV).

NCT ID: NCT00048529 Suspended - Gastric Cancer Clinical Trials

Study of T900607-Sodium in Subjects With Previously Treated Gastric Cancer or Adenocarcinoma of the Esophagus

Start date: September 2002
Phase: Phase 2
Study type: Interventional

This is a clinical research study of T900607-sodium to determine if it is effective and safe in treating gastric cancer and adenocarcinoma of the esophagus. Patients will be treated on a weekly basis with an intravenous injection of the study drug.

NCT ID: NCT00038454 Suspended - Clinical trials for Cardiovascular Disease

Phase II Study To Evaluate The Safety and Efficacy of Hemoglobin Raffimer in Patients Undergoing First Time CABG Surgery

Start date: n/a
Phase: Phase 2/Phase 3
Study type: Interventional

To evaluate the efficacy of Hemolinkā„¢ in combination with Intraoperative Autologous Donation (IAD) versus control (IAD alone) in facilitating avoidance of allogeneic RBC transfusion during and following primary CABG surgery

NCT ID: NCT00033956 Suspended - Clinical trials for IL-2 Induced Hypotension

Evaluation of M40403 for the Prevention of Dose Limiting Toxicities of High Dose IL-2

Start date: December 2001
Phase: Phase 1/Phase 2
Study type: Interventional

The clinical use of IL-2 is currently limited by development of dose-dependent hypotension (systolic blood pressure (SBP) < 90 mm Hg). The overall outcome is constant across sites with 20-50% of the patients requiring ICU management because of unresponsive hypotension and hyporeactivity (loss of response to vasoconstrictors). Because of the dose-limiting side effects, the duration of IL-2 dosing is frequently curtailed. Thus, hemodynamic toxicities have limited the usefulness of IL-2 therapy. M40403 has prevented both the hypotension and hyporeactivity associated with IL-2 treatment in preclinical studies. This trial will study the safety and efficacy of M40403 in the prevention or reduction of hypotension in patients receiving IL-2 therapy.

NCT ID: NCT00008775 Suspended - Cystic Fibrosis Clinical Trials

Pressure Support Ventilation During CF Exacerbations

Start date: n/a
Phase: N/A
Study type: Interventional

Chest physiotherapy is recognized as a mainstay of cystic fibrosis therapy, and is particularly important during treatment of pulmonary exacerbations. For some patients, especially those with moderate to severe compromise of lung function, this therapy may impose a high demand in the work of breathing and energy expenditure. The goal of this study is to evaluate the effectiveness of adding pressure support ventilation (PSV) during chest physiotherapy sessions in patients with cystic fibrosis with moderate to severe lung function compromise being treated for a pulmonary exacerbation.

NCT ID: NCT00005110 Suspended - Cystic Fibrosis Clinical Trials

A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

Start date: n/a
Phase: N/A
Study type: Interventional

Long term use of bronchodilators in CF is beneficial to the improvement of pulmonary function and symptoms. This study is investigating the long-term benefit of administration of the drug Salmeterol, a bronchodilator. Salmeterol will be compared to albuterol or placebo. The medication will be inhaled twice a day for 6 months.

NCT ID: NCT00004999 Suspended - HIV Infections Clinical Trials

Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients

Start date: August 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to look at the effectiveness of giving a new anti-HIV drug (AG1549) plus Viracept (nelfinavir) plus Combivir (a tablet containing zidovudine plus lamivudine) to HIV-infected patients who are not taking anti-HIV drugs.

NCT ID: NCT00004998 Suspended - HIV Infections Clinical Trials

Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients

Start date: November 1999
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if two different doses of AG1549 plus other anti-HIV drugs are safe and effective in HIV-infected patients who are not taking anti-HIV drugs.

NCT ID: NCT00004300 Suspended - Mental Retardation Clinical Trials

Phase II Study of Stereotypes and Mental Retardation: Neurobiological Basis

Start date: n/a
Phase: Phase 2
Study type: Interventional

OBJECTIVES: I. Determine differences between persons with repetitive behavior disorders and matched controls on measures of motor control relevant to basal ganglia pathophysiology. II. Determine the efficacy of bromocriptine, a dopamine agonist, in the treatment of stereotyped behavior and related behavior disorders. III. Determine the efficacy of sertraline hydrochloride, a selective serotonin uptake inhibitor, in the treatment of repetitive behavior disorders. IV. Identify behavioral, environmental, and biological variables with differential drug treatment response.

NCT ID: NCT00003067 Suspended - Clinical trials for Brain and Central Nervous System Tumors

Biological Therapy in Treating Patients With Primary or Advanced Glioma

Start date: July 1997
Phase: Phase 2
Study type: Interventional

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells in patients with primary or advanced glioma. PURPOSE: Clinical trial to study the effectiveness of biological therapy with interleukin-2 and lymphokine-activated killer cells in treating patients who have primary, recurrent, or refractory malignant glioma.